Patents by Inventor Michael Shetzline

Michael Shetzline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of IL-1 beta Binding Antibodies
    Publication number: 20210371512
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Application
    Filed: March 9, 2021
    Publication date: December 2, 2021
    Inventors: Tom THUREN, Michael SHETZLINE, Andrew ZALEWSKI
  • Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
    Patent number: 10975145
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • METHOD OF TREATING PEDIATRIC DISORDERS
    Publication number: 20200179486
    Abstract: The invention provides methods for treating pediatric inflammatory bowel disease patients using vedolizumab.
    Type: Application
    Filed: April 26, 2018
    Publication date: June 11, 2020
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria Rosario, Michael A. Shetzline, William R. Treem
  • Use of IL-1ß Binding Antibodies
    Publication number: 20170275358
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Application
    Filed: April 10, 2017
    Publication date: September 28, 2017
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
    Patent number: 9683038
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 20, 2017
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Use of IL-1 beta Binding Antibodies
    Publication number: 20140356356
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Application
    Filed: September 27, 2012
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Single-cell biosensor for the measurement of GPCR ligands in a test sample
    Publication number: 20090226949
    Abstract: The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs.
    Type: Application
    Filed: March 4, 2009
    Publication date: September 10, 2009
    Applicant: Duke University
    Inventors: Lawrence S. Barak, Michael A. Shetzline, Robert H. Oakley, Marc G. Caron
  • Single-cell biosensor for the measurement of GPCR ligands in a test sample
    Patent number: 7541151
    Abstract: The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: June 2, 2009
    Assignee: Duke University
    Inventors: Lawrence S. Barak, Michael A. Shetzline, Robert H. Oakley, Marc G. Caron
  • SINGLE-CELL BIOSENSOR FOR THE MEASUREMENT OF GPCR LIGANDS IN A TEST SAMPLE
    Publication number: 20090075314
    Abstract: The present invention is related to the detection of GPCR ligands in a test sample by using a single cell biosensor expressing a GPCR. Preferably, the test sample is derived from a biological or environmental sample. This invention may be used to detect the presence of a disease or to detect the presence of a harmful agent in the environment. Included in the present invention is an array of biosensors that detect ligands of various GPCRs.
    Type: Application
    Filed: June 4, 2002
    Publication date: March 19, 2009
    Inventors: Lawrence S. Barak, Michael A. Shetzline, Robert H. Oakley, Marc G. Caron